TY - JOUR
T1 - Polymer conjugate of a microtubule destabilizer inhibits lung metastatic melanoma
AU - Yang, Ruinan
AU - Mondal, Goutam
AU - Ness, Rachel A.
AU - Arnst, Kinsie
AU - Mundra, Vaibhav
AU - Miller, Duane D.
AU - Li, Wei
AU - Mahato, Ram I.
N1 - Funding Information:
We would like to acknowledge the National Institutes of Health (NIH) (R01CA148706 to WL and DDM) and the Faculty Start-up fund from the University of Nebraska Medical Center to RIM for financial support.
Publisher Copyright:
© 2017 Elsevier B.V.
PY - 2017/3/10
Y1 - 2017/3/10
N2 - Melanoma is the most aggressive type of skin cancer. It is highly metastatic, migrating through lymph nodes to distant sites of the body, especially to lungs, liver and brain. Systemic chemotherapy remains the mainstay of treatment; however, the development of multidrug resistance (MDR) restricts the efficacy of current chemotherapeutic drugs. We synthesized a series of microtubule destabilizers, substituted methoxybenzoyl-ary-thiazole (SMART) compounds, which inhibited tubulin polymerization and effectively circumvented MDR. Due to poor water solubility of SMART compounds, co-solvent delivery is required for their systemic administration, which is usually associated with hepatotoxicity, nephrotoxicity and hemolysis. To solve this problem and also to increase circulation time, we synthesized a new SMART analogue, SMART-OH, and its polymer-drug conjugate, methoxy-poly (ethylene glycol)-block-poly (2-methyl-2-carboxyl-propylene carbonate-graft-SMART-graft-dodecanol) (abbreviated as P-SMART), with 14.3 ± 2.8% drug payload of SMART-OH. Similar to its parent drug, P-SMART showed significant anticancer activity against melanoma cells in cytotoxicity, colony formation, and cell invasion studies. In addition, P-SMART treatment led to cell cycle arrest at G2/M phase and cell accumulation in sub-G1 phase. We established a model of metastatic melanoma to the lung in C57/BL6 albino mice to determine in vivo efficacy of P-SMART and SMART-OH at the dose of 20 mg/kg. P-SMART treatment resulted in significant inhibition of tumor growth and prolonged mouse median survival. In conclusion, P-SMART, a novel polymer-microtubule destabilizer conjugate, has the potential to treat metastatic melanoma.
AB - Melanoma is the most aggressive type of skin cancer. It is highly metastatic, migrating through lymph nodes to distant sites of the body, especially to lungs, liver and brain. Systemic chemotherapy remains the mainstay of treatment; however, the development of multidrug resistance (MDR) restricts the efficacy of current chemotherapeutic drugs. We synthesized a series of microtubule destabilizers, substituted methoxybenzoyl-ary-thiazole (SMART) compounds, which inhibited tubulin polymerization and effectively circumvented MDR. Due to poor water solubility of SMART compounds, co-solvent delivery is required for their systemic administration, which is usually associated with hepatotoxicity, nephrotoxicity and hemolysis. To solve this problem and also to increase circulation time, we synthesized a new SMART analogue, SMART-OH, and its polymer-drug conjugate, methoxy-poly (ethylene glycol)-block-poly (2-methyl-2-carboxyl-propylene carbonate-graft-SMART-graft-dodecanol) (abbreviated as P-SMART), with 14.3 ± 2.8% drug payload of SMART-OH. Similar to its parent drug, P-SMART showed significant anticancer activity against melanoma cells in cytotoxicity, colony formation, and cell invasion studies. In addition, P-SMART treatment led to cell cycle arrest at G2/M phase and cell accumulation in sub-G1 phase. We established a model of metastatic melanoma to the lung in C57/BL6 albino mice to determine in vivo efficacy of P-SMART and SMART-OH at the dose of 20 mg/kg. P-SMART treatment resulted in significant inhibition of tumor growth and prolonged mouse median survival. In conclusion, P-SMART, a novel polymer-microtubule destabilizer conjugate, has the potential to treat metastatic melanoma.
KW - Metastatic melanoma
KW - Microtubule destabilizer
KW - Nanomedicine
KW - Polymer drug conjugate
UR - http://www.scopus.com/inward/record.url?scp=85010825415&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85010825415&partnerID=8YFLogxK
U2 - 10.1016/j.jconrel.2017.01.028
DO - 10.1016/j.jconrel.2017.01.028
M3 - Article
C2 - 28130039
AN - SCOPUS:85010825415
VL - 249
SP - 32
EP - 41
JO - Journal of Controlled Release
JF - Journal of Controlled Release
SN - 0168-3659
ER -